Equity Overview
Price & Market Data
Price: $15.99
Daily Change: -$0.11 / 0.69%
Daily Range: $15.98 - $16.54
Market Cap: $1,323,767,568
Daily Volume: 719,749
Performance Metrics
1 Week: -5.16%
1 Month: 37.25%
3 Months: 20.14%
6 Months: 85.71%
1 Year: 94.53%
YTD: 110.7%
Company Details
Employees: 165
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.